Abstract: The invention relates to antibodies and antigen-binding fragment thereof capable of binding to IL13R?2. The antibodies and antigen-binding fragment thereof are in particular useful in constructing chimeric antigen receptors (CARs) and in CAR based immunotherapy for treatment of IL13R?2-expressing cancer diseases.

Abstract: T-cells useful in T-cell immunotherapy comprise a CAR, TCR and/or nucleic acid sequence(s) encoding a CAR and/or a TCR. The T-cells also comprise HP-NAP, an immunological equivalent fragment thereof and/or nucleic acid sequence(s) encoding HAP-NAP and/or an immunological equivalent fragment thereof. The T-cells have improved effects in immunotherapy including improved cytotoxicity, stimulation of chemokine and cytokine secretion, promoting dendritic cell maturation and recruitment and activation of innate immune cells.

Abstract: The invention provides a hexon Tat-PTD modified adenovirus, a gene delivery vector based on the modified adenovirus that enhances gene delivery efficiency, and an oncolytic agent based on the modified adenovirus that enhances tumor cell killing efficiency and improves therapeutic outcome.

Abstract: The invention provides a hexon Tat-PTD modified adenovirus, a gene delivery vector based on the modified adenovirus that enhances gene delivery efficiency, and an oncolytic agent based on the modified adenovirus that enhances tumor cell killing efficiency and improves therapeutic outcome.

Abstract: A method of providing expression of a molecule in a prostate cell, prostate cancer cell or breast cancer cell comprises introducing into the cell a TARP promoter or a transcriptionally active fragment thereof, operatively linked to a heterologous polynucleotide that codes for the molecule, under conditions effective to direct expression of the molecule in the cell. A method of treating or preventing a prostate-related or breast-related disorder comprises introducing into a cell of a subject in need thereof a TARP promoter, or a transcriptionally active fragment thereof, operatively linked to a heterologous polynucleotide that codes for a molecule capable of killing the cell or capable of preventing the disorder. An isolated polynucleotide sequence comprises a TARP promoter, or a transcriptionally active fragment thereof, operatively linked to a heterologous expressible nucleotide sequence, or operatively linked to other expression control sequences.

Abstract: This invention provides nucleic acids containing sequences from a TCR? transcript from prostate epithelial cells and many breast cancer cells and a T-cell receptor gamma Alternate Reading frame Protein (“TARP”) expressed from the translation of those sequences. Vaccines made from TARP are useful in raising immune responses to cells in which the protein is expressed, including prostate cancer cells and cells of many breast cancers. The invention also provides methods for diagnosing the presence of prostate cancer and TARP-expressing breast cancers, as well as methods of administering TARP and nucleic acids encoding TARP to subjects.